StageIPO | IPO
Date of IPO4/4/2011
Missing: Tranzyme Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Tranzyme Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Tranzyme Pharma Patents
Tranzyme Pharma has filed 10 patents.
Macrocycles, Drug discovery, Hormonal agents, Chelating agents, Peptides
Macrocycles, Drug discovery, Hormonal agents, Chelating agents, Peptides
Latest Tranzyme Pharma News
Nov 27, 2016
Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Tranzyme Pharma, Inc. formerly Neokimia Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 23:18 EST 26 Nov 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Tranzyme Pharma, Inc. formerly Neokimia Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Tranzyme Pharma, Inc. formerly Neokimia Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Tranzyme Pharma, Inc. formerly Neokimia Inc. since January 2007. Key Findings Provides intelligence on Tranzyme Pharma, Inc. formerly Neokimia Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Tranzyme Pharma, Inc. formerly Neokimia Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Tranzyme Pharma, Inc. formerly Neokimia Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Tranzyme Pharma, Inc. formerly Neokimia Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Tranzyme Pharma Frequently Asked Questions (FAQ)
When was Tranzyme Pharma founded?
Tranzyme Pharma was founded in 1998.
Where is Tranzyme Pharma's headquarters?
Tranzyme Pharma's headquarters is located at 4819 Emperor Boulevard, Durham.
What is Tranzyme Pharma's latest funding round?
Tranzyme Pharma's latest funding round is IPO.
How much did Tranzyme Pharma raise?
Tranzyme Pharma raised a total of $54.3M.
Who are the investors of Tranzyme Pharma?
Investors of Tranzyme Pharma include BDC Venture Capital, Thomas McNerney & Partners, H.I.G. BioHealth Partners, Quaker BioVentures, Pacific Venture Group and 12 more.
Who are Tranzyme Pharma's competitors?
Competitors of Tranzyme Pharma include Acceleron Pharma, Orexigen Therapeutics, Threshold Pharmaceuticals, ActoGeniX, Probiodrug and 12 more.
Compare Tranzyme Pharma to Competitors
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.
Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.
Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Dynogen is a biopharmaceutical company developing drugs for gastrointestinal (GI) and genitourinary (GU) disorders, including irritable bowel syndrome (IBS) and overactive bladder (OAB). Dynogen focuses on compounds that have previously been in the clinic and therefore have known safety and pharmacokinetic profiles.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.